ALB and chronic kidney disease: Interestingly, the use of ACEI/ARBs therapy for persons with CKD or urine albumin excretion >30 mg/24 h (or equivalent) had dramatically increased from 38.7% (95% CI, 34.4–43.3) in 2013/14 to 60.9% (95% CI, 56.8–64.8) in 2021/22.